Poster ID
P-36
Poster Title
The Role of Government in Driving the Future of Precision Medicine through Omic Technologies Research in the Philippines
Authors
Aimee Yvonne Criselle L. Aman - a,b
Georgina Rae C. Cababa - a
John Philip P. Depatillo- a
Melissa C. Bulao - a
Paul Ernest N. de Leon- a
a- Department of Science and Technology - Philippine Council for Health Research and Development, Saliksik Bldg., Sikap St., DOST Compound, Gen. Santos Ave., Bicutan, Taguig, PHILIPPINES
b- DOST S&T Fellows Program, DOST Central Office, DOST Compound, Gen. Santos Ave., Bicutan, Taguig, PHILIPPINES
Georgina Rae C. Cababa - a
John Philip P. Depatillo- a
Melissa C. Bulao - a
Paul Ernest N. de Leon- a
a- Department of Science and Technology - Philippine Council for Health Research and Development, Saliksik Bldg., Sikap St., DOST Compound, Gen. Santos Ave., Bicutan, Taguig, PHILIPPINES
b- DOST S&T Fellows Program, DOST Central Office, DOST Compound, Gen. Santos Ave., Bicutan, Taguig, PHILIPPINES
Abstract
The Department of Science and Technology - Philippine Council for Health Research and Development (DOST-PCHRD), as the lead coordinating body of the Philippine National Health Research System (PNHRS) and sectoral planning body for health R&D of the DOST, strongly supports the building of an omics-enabled future for the Filipinos through precision medicine research and development. The government puts premium investment on multi-omics research and development for health through different programs, projects, and capacity-building activities under the Omic Technologies for Health R&D Program (Omics Program) of the Research and Development Management Division (RDMD) of DOST-PCHRD. Other PCHRD R&D priority programs, specifically on Re-emerging and Emerging Diseases (RED), Brain and Mental Health (BMH), Nutrition and Food Safety (NFS), Diagnostics, and Drug Discovery and Development (Tuklas Lunas) also utilize -omic technologies in different capacities.
Between January to June 2026, the Omics Program supported the implementation of 31 active projects, with relevant topics from pediatric conditions (rare diseases, pediatric brain tumors, malnutrition in children), women’s health and fetomaternal conditions (endometrioma, gestational trophoblastic disease, pre-eclampsia, post-partum depression), infectious diseases (tuberculosis, dengue), and non-communicable and chronic diseases (systemic lupus erythematosus, rheumatic heart disease, dementia, cancers), utilizing a gamut of different omic technologies. These initiatives employed various -omic technologies such as genomics, transcriptomics, proteomics, and metabolomics, as well as disease modelling to facilitate the discovery of biomarkers and drug targets, and provide mechanistic insights on the pathophysiology of these conditions. The main goal of the Omics Program is for the outputs of the supported R&D work to be utilized in the next phases of biomarker development, drug target identification, and elucidation of disease mechanisms that will drive progress in diagnostics and therapeutics. A precision medicine-based research agenda and roadmap is key in the planning of these next phases.
Between January to June 2026, the Omics Program supported the implementation of 31 active projects, with relevant topics from pediatric conditions (rare diseases, pediatric brain tumors, malnutrition in children), women’s health and fetomaternal conditions (endometrioma, gestational trophoblastic disease, pre-eclampsia, post-partum depression), infectious diseases (tuberculosis, dengue), and non-communicable and chronic diseases (systemic lupus erythematosus, rheumatic heart disease, dementia, cancers), utilizing a gamut of different omic technologies. These initiatives employed various -omic technologies such as genomics, transcriptomics, proteomics, and metabolomics, as well as disease modelling to facilitate the discovery of biomarkers and drug targets, and provide mechanistic insights on the pathophysiology of these conditions. The main goal of the Omics Program is for the outputs of the supported R&D work to be utilized in the next phases of biomarker development, drug target identification, and elucidation of disease mechanisms that will drive progress in diagnostics and therapeutics. A precision medicine-based research agenda and roadmap is key in the planning of these next phases.
Digital Poster